NIH Locks Down March Meetings for Health Research Grants
Published Date: 2/18/2026
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in March 2026 to review and decide on important health research grant applications. These meetings protect private info and trade secrets while helping decide which projects get funding. Scientists and researchers applying for grants should note these dates as they impact which studies get support and money.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 0 costs, 2 mixed.
March Panels Decide Grant Funding
Multiple NIH review panels will hold virtual meetings on March 17, March 18-19, and March 20, 2026 to review and evaluate grant applications. If you apply for these grants or fellowships, those meetings will determine which projects and fellowships receive NIH support and funding.
Closed Reviews Protect Trade Secrets
The NIH announced closed meetings in March 2026 that will be closed under sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., and pursuant to section 1009 of the Federal Advisory Committee Act. You (as a grant applicant) can have confidential trade secrets, patentable material, and personal information kept out of the public record during these grant-review meetings.
Specialized Panels Listed by Date
The notice lists specific closed virtual panels and dates in March 2026 — for example: a Special Emphasis Panel on neurodevelopment, an Oncology study section (March 18-19), Drug Discovery and Molecular Pharmacology (March 20), Complementary and Integrative Health (March 20), an RFA-CA-25-002 R33 panel (March 20), and a Fellowships panel for Kidney/Urology (March 20). These panels will review and evaluate the relevant grant and fellowship applications on those dates.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2026-03198, Endangered and Threatened Wildlife; 90-Day Finding on Petitions To List the Atlantic Horseshoe Crab (Limulus Polyphemus) Under the Endangered Species Act
The government reviewed requests to protect the Atlantic horseshoe crab as endangered but found there isn’t enough solid evidence to do so right now. This means no new rules or protections will happen immediately, keeping things steady for fishermen and businesses. The decision was made quickly—within 90 days—to keep everyone informed and on track.
Next: 2026-03201, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding a closed virtual meeting on March 3, 2026, to review important grant applications for biomedical research. This meeting was delayed due to a government shutdown but is now urgent to keep funding on track for key health projects. Scientists applying for grants and the public waiting on research progress are affected by this quick reschedule.